Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox

Lignende værker

• Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
  af: Taher, Ali T., et al.
  Udgivet: (2013)
• Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
  af: Taher, Ali T, et al.
  Udgivet: (2013)
• Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
  af: Taher, Ali T, et al.
  Udgivet: (2016)
• Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
  af: Taher AT, et al.
  Udgivet: (2016-12-01)
• Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload
  af: Aydinok, Yesim, et al.
  Udgivet: (2015)